A researcher's guide to Semaglutide — mechanism, findings, dosing context, and where to compare prices.
Semaglutide is a synthetic analog of glucagon-like peptide-1 (GLP-1), a hormone naturally produced in the gut in response to food intake. It was originally developed as a treatment for type 2 diabetes and has since been studied extensively for its effects on appetite regulation and body weight.
As a GLP-1 receptor agonist, Semaglutide binds to and activates GLP-1 receptors in the pancreas, brain, and gastrointestinal tract. This activation produces several downstream effects that researchers have studied in detail over the past two decades.
Semaglutide works through several interconnected pathways:
Semaglutide has a half-life of approximately 7 days due to structural modifications that slow its degradation — substantially longer than native GLP-1, which has a half-life of just 1–2 minutes.
The STEP clinical trial program — a series of large randomized controlled trials — established Semaglutide as among the most effective pharmacological interventions studied for weight reduction. In STEP 1, participants receiving 2.4mg weekly injections achieved a mean weight loss of approximately 14.9% of body weight over 68 weeks, compared to 2.4% in the placebo group.
The SELECT trial (2023) examined Semaglutide's cardiovascular effects in adults with obesity but without diabetes. The study reported a 20% reduction in major adverse cardiovascular events compared to placebo — a significant finding that expanded research interest in GLP-1 agonists beyond metabolic applications.
Research has consistently shown improvements in HbA1c, fasting glucose, blood pressure, and lipid profiles in study subjects receiving Semaglutide. These metabolic effects are thought to be both direct and secondary to weight reduction.
Semaglutide acts on the GLP-1 receptor only. Tirzepatide, a newer compound, adds GIP receptor agonism, and clinical studies have shown modestly greater weight loss on average. Retatrutide goes further still, adding glucagon receptor agonism for a triple mechanism — early trials showed average weight loss exceeding 24% of body weight, the highest reported in any pharmacological trial to date.
For researchers, this progression represents an important context for understanding where Semaglutide fits in the GLP-1 landscape.
Clinical trials with Semaglutide typically used a dose-escalation protocol, starting at 0.25mg weekly and increasing gradually to a maintenance dose of 1mg or 2.4mg depending on the application. This titration approach was designed to minimize gastrointestinal side effects during the adjustment period.
Common package sizes available from research suppliers are 2mg, 5mg, 10mg, and 15mg vials. Larger vials typically offer a lower cost per mg.
See current prices across US research peptide suppliers, sorted by cost per mg.
View Price Comparison →When evaluating research peptide suppliers for Semaglutide, researchers typically consider:
Clinical trial data shows Tirzepatide produces greater average weight loss (approximately 20–22% of body weight in SURMOUNT trials) compared to Semaglutide (approximately 15% in STEP trials). Tirzepatide's dual GLP-1/GIP mechanism is thought to drive the additional effect. That said, Semaglutide has a longer and better-characterized research history, which some researchers prefer.
Prices vary by supplier and package size. As a general benchmark, the cost per mg for research Semaglutide typically ranges from $7 to $25 per mg depending on the supplier and quantity. Using a price comparison tool to evaluate cost per mg across suppliers is the most efficient way to find current best value.
Yes. Semaglutide is a peptide and dissolves readily in bacteriostatic water, which is the standard reconstitution medium used in research settings. The typical reconstitution approach uses 1–2ml of bacteriostatic water per vial.